{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:05:34Z","timestamp":1781327134252,"version":"3.54.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in \u223c60% of patients. Atezolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets programmed death\u2013ligand 1 and has previously shown antitumor activity in several tumor types. In a phase 1b\/2 trial (NCT02596971), we evaluated the safety and efficacy of atezolizumab in combination with R-CHOP (atezo\u2013R-CHOP; for 6-8 cycles) in patients with previously untreated DLBCL. Patients achieving a complete response (CR) at the end of induction received consolidation therapy with atezolizumab on day 1 of each 21-day cycle for an additional 17 cycles. Overall, 42 patients with DLBCL were included in this analysis. The primary endpoint, CR rate at the end of induction, as assessed by an independent review committee (modified Lugano 2014 criteria), was 77.5% (95% confidence interval [CI], 64.0-87.7; n\u00a0= 40). Investigator-assessed progression-free survival and overall survival at 3 years were 77.4% (95% CI, 59.7-88.0) and 87.2% (95% CI, 71.9-94.5), respectively. All treated patients experienced \u22651 adverse event (AE; 32 patients [76.2%] had grade 3-4 AE). One patient had a fatal AE (unconfirmed progressive multifocal leukoencephalopathy) that was considered related to atezolizumab and rituximab, and 17 patients (40.5%) experienced atezolizumab-related AEs of special interest. In previously untreated patients with DLBCL, atezo\u2013R-CHOP demonstrated encouraging clinical efficacy and a safety profile consistent with the known toxicities of the individual drugs. This trial was registered at www.clinicaltrials.gov as #NCT02596971.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008344","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T15:07:46Z","timestamp":1666796866000},"page":"1488-1495","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"given":"Anas","family":"Younes","sequence":"first","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"2Rocky Mountain Cancer Centers & US Oncology, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"3Georgetown University Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"4Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-2843","authenticated-orcid":false,"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[{"name":"5Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe H.","family":"Hahn","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Royal Adelaide and Queen Elizabeth Hospital, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khan","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1947-1032","authenticated-orcid":false,"given":"Gerardo","family":"Musuraca","sequence":"additional","affiliation":[{"name":"10Hematology Unit, IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"12Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Yuen","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Calvary Mater, Newcastle, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Raval","sequence":"additional","affiliation":[{"name":"14Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Shivhare","sequence":"additional","affiliation":[{"name":"15Data and Statistical Science, Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina G.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"16Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gila","family":"Sellam","sequence":"additional","affiliation":[{"name":"16Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"17US Oncology Research, Willamette Valley Cancer Institute\/US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"issue":"5","key":"2023042114593998800_bib1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2023042114593998800_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 5","key":"2023042114593998800_bib3","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"2023042114593998800_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"16","key":"2023042114593998800_bib5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023042114593998800_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A\u00a0randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"31","key":"2023042114593998800_bib7","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023042114593998800_bib8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"2023042114593998800_bib9","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023042114593998800_bib10","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 2","key":"2023042114593998800_bib11","article-title":"The POLARIX study: polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma","volume":"138","author":"Tilly","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023042114593998800_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023042114593998800_bib13","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41598-021-85329-9","article-title":"Next generation of anti-PD-L1 atezolizumab with enhanced anti-tumor efficacy in\u00a0vivo","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"issue":"10030","key":"2023042114593998800_bib14","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"2023042114593998800_bib15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10031","key":"2023042114593998800_bib16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"15","key":"2023042114593998800_bib17","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.1200\/JCO.2020.38.15_suppl.8053","article-title":"Atezolizumab\u00a0+ obinutuzumab\u00a0+ venetoclax in patients with relapsed or refractory diffuse large B-cell lymphomas (R\/R DLBCL): primary analysis of a phase II trial from LYSA","volume":"38","author":"Herbaux","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023042114593998800_bib18","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti\u2013ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti\u2013PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2023042114593998800_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.seminoncol.2010.09.008","article-title":"Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies","volume":"37","author":"Ascierto","year":"2010","journal-title":"Semin Oncol"},{"issue":"6","key":"2023042114593998800_bib20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br J Haematol"},{"issue":"27","key":"2023042114593998800_bib21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023042114593998800_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2023042114593998800_bib23","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2023042114593998800_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","article-title":"ClonoSEQ assay for the detection of lymphoid malignancies","volume":"19","author":"Monter","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"2023042114593998800_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-021-03241-4","article-title":"Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial","volume":"115","author":"Nowakowski","year":"2022","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"2023042114593998800_bib26","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood-2019-123433","article-title":"Final analysis of GOYA: a randomized, open-label, phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma","volume":"134","author":"Sehn","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2023042114593998800_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"2023042114593998800_bib28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"Suppl 13","key":"2023042114593998800_bib29","doi-asserted-by":"crossref","first-page":"S1516","DOI":"10.21037\/jtd.2017.12.52","article-title":"Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients","volume":"10","author":"Remon","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"issue":"5","key":"2023042114593998800_bib30","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1488\/2045843\/blooda_adv-2022-008344-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/8\/1488\/2045843\/blooda_adv-2022-008344-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T15:54:28Z","timestamp":1682092468000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/8\/1488\/486901\/Safety-and-efficacy-of-atezolizumab-with-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,4,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008344","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}